发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline
发布时间
162 天前
2026-04-29 11:50:56 UTC
源站更新
162 天前
2026-04-29 11:51:43 UTC
首次抓取
162 天前
2026-04-29 12:00:37 UTC
艾伯维第一季度营收和利润均超预期，主要得益于新型免疫药物 Skyrizi 和 Rinvoq 的强劲需求，有效抵消了昔日王牌药物修美乐因专利到期导致的销量下滑。
AbbVie beat quarterly revenue and profit expectations as strong demand for newer immunology drugs Skyrizi and Rinvoq offset the decline of its former blockbuster Humira. The company also raised its full-year earnings forecast following growth in its neuroscience and Botox
用于追踪这条内容的来源与记录标识。
